

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
12 May 2005 (12.05.2005)

PCT

(10) International Publication Number
WO 2005/042733 A1

(51) International Patent Classification?: **C12N 7/00,**
C07K 14/02, C12Q 1/70

(21) International Application Number:
PCT/AU2004/001440

(22) International Filing Date: 20 October 2004 (20.10.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2003905776 21 October 2003 (21.10.2003) AU
2004900962 25 February 2004 (25.02.2004) AU

(71) Applicants (for all designated States except US): **MELBOURNE HEALTH** [AU/AU]; 10th Floor, Connibere Building, Royal Melbourne Hospital, Flemington Road, Victoria, Melbourne 3052 (AU). **AUSTIN HEALTH** [AU/AU]; Studley Road, Heidelberg, Victoria 3081 (AU). **SOUTHERN HEALTH** [AU/AU]; Monash Medical Centre, 246 Clayton Road, Clayton, Victoria 3168 (AU). **BAYSIDE HEALTH** [AU/AU]; Commercial Road, Melbourne, Victoria 3004 (AU). **ST. VINCENT'S HOSPITAL (MELBOURNE) LTD.** [AU/AU]; Trading as St0 Vincent's Hospital Melbourne, Victoria Parade, Fitzroy, Victoria 3065 (AU).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BARTHOLOMEUSZ, Angeline, Ingrid** [AU/AU]; 64 Miller Street, Carnegie, Victoria 3163 (AU). **LOCARNINI, Stephen, Alister** [AU/AU]; 13 Carlisle Avenue, Victoria, Kilda East 3183 (AU). **AYRES, Anna**

[AU/AU]; 4 Ferry Crescent, West Brunswick, Victoria 3055 (AU). **YUEN, Lilly, Ka Wai** [AU/AU]; 17 Summit Drive, Bulleen, Victoria 3105 (AU). **SASADEUSZ, Joseph, John** [AU/AU]; 14 King Street, Camberwell, Victoria 3124 (AU).

(74) Agents: **HUGHES, E., John, L.** et al.; Davies Collison Cave, 1 Nicholson Street, Victoria, Melbourne 3000 (AU).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **HBV VARIANTS DETECTION AND APPLICATION**

(57) Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.